Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2028-11-01
Target enrollment:
Participant gender:
Summary
China with high incidence of esophageal cancer, the number of new cases and deaths account
for about 50% of the world every year. In the past few decades, surgery, radiotherapy,
chemotherapy and other treatments were continuously improved, however, the mortality of
esophageal squamous cell carcinoma patients was not significantly decreased.
For patients with locally advanced esophageal cancer, direct surgery is not effective. It is
difficult to achieve radical resection by surgery merely, and even if many patients receive
surgery, they may eventually have tumor recurrence and poor survival rate. Therefore, it is
necessary to explore effective perioperative neoadjuvant treatment to reduce the risk of
postoperative recurrence and improve the postoperative survival rate of patients.
According to the reports, the expression of PD-L1 in esophageal cancer was about 41.4%.
Therefore, PD-1/ PD-L1 immunocheckpoint inhibitor may become a new method for the treatment
of esophageal cancer. Preliminary clinical results showed that immunotherapy combined with
chemoradiotherapy provided a synergies antitumor effect. Multiple clinical results showed
that Carrillizumab provided higher overall response rate for advanced esophageal cancer.
However, in patients with locally advanced esophageal cancer, the efficacy of Carrillizumab
combined with chemotherapy and apatinib for sequential radical surgery is still unclear. The
purpose of this study is to observe and evaluate the efficacy and safety of Carrillizumab
combined with chemotherapy and antiangiogenic drugs in the neoadjuvant therapy of resectable
esophageal squamous cell carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University